Industry · August 29, 2026

Peptide Sciences Shut Down — What Canadian Researchers Need to Know

On March 6, 2026, Peptide Sciences — for years one of the largest and most-recognized research peptide vendors in North America — posted a notice that it had voluntarily ceased all operations and discontinued its entire catalogue. The site went dark the same day. For thousands of researchers who treated it as the default source, the obvious questions are what happened, and what now. For Canadian researchers specifically, the answers are more interesting than the headlines.

What happened

The shutdown didn't come out of nowhere. Over the preceding 18 months, US federal enforcement against research peptide vendors escalated sharply: dozens of FDA warning letters went out to vendors through 2025, and at least one major competitor's warehouse was physically raided in mid-2025. In early 2026, proposed US legislation (the SAFE Drugs Act) took direct aim at the research-chemical model itself — targeting the sale of compounds identical to approved drugs without a drug application.

Peptide Sciences appears to have read the trajectory and exited voluntarily rather than waiting for enforcement to arrive. No reopening has been announced, and the closure is widely treated as permanent.

Why this matters differently in Canada

The enforcement wave driving the US consolidation is American — FDA letters, US legislation, US raids. It does not automatically translate across the border, and it has produced a quietly significant shift:

• Domestic Canadian vendors matter more than ever. With major US vendors closing or retreating, importing from the remaining US sources has become both riskier (customs exposure on substances that are prescription or unapproved drugs in Canada — see Are Peptides Legal in Canada?) and less reliable. The practical answer for Canadians was always domestic sourcing; now it's also the only stable one.
• Quality documentation is the new differentiator. The vendors that survive regulatory attention tend to be the ones with rigorous, published third-party testing. That's a selection pressure that quietly benefits careful researchers.
• Orphaned researchers need new references. Peptide Sciences' product pages doubled as informal documentation for a lot of people. That's part of why this site exists — vendor-independent reference material doesn't disappear when a store does.

What to do now

1. Re-source domestically. The Canadian vendor directory lists vendors shipping from within Canada with published lab documentation, including our featured partner Regen BioSignals.
2. Audit what you have. If you hold stock from a closed vendor, its COAs may no longer be accessible online. Download or screenshot documentation for anything still in your fridge — and going forward, save the COA PDF with every order.
3. Verify harder. A market in flux attracts opportunists. The COA verification guide covers exactly what a real lab report shows and the red flags that disqualify a vendor.
4. Keep your own records. When vendor websites can vanish overnight, your protocol log — compound, batch, source, dates — becomes the only durable record. The tracking app exists for precisely this.

The bigger picture

Consolidation was probably inevitable: the research peptide market grew faster than its quality practices, and the GLP-1 boom drew mainstream and regulatory attention simultaneously. The likely end state is a smaller number of vendors with genuinely rigorous testing — which, for researchers who were already reading COAs, is not a bad trade.